Sharps Technology Reports FY Financial Results

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Apr 06 2026

0mins

STSS+3.78%

Should l Buy STSS?

Source: seekingalpha

Financial Overview: Sharps Technology's FY GAAP EPS stands at -$10.68, indicating significant financial challenges that may lead to a decline in investor confidence.
Revenue Performance: The reported revenue of $0.2 million falls short of market expectations, highlighting the company's competitive disadvantages that could impact future financing capabilities and operational strategies.
Financial Health: The ongoing losses and low revenue levels may compel Sharps Technology to reassess its business model and cost structure to achieve sustainable growth and attract investor interest.
Market Reaction Outlook: Given the poor financial performance, the market is expected to react negatively to Sharps Technology's stock price, prompting investors to closely monitor subsequent strategic adjustments and management responses.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy STSS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on STSS

About STSS

Sharps Technology, Inc. is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Sharps Technology Reports FY Results

Apr 06 2026seekingalpha

Financial Overview: Sharps Technology reported a FY GAAP EPS of -$10.68, indicating significant challenges in profitability that could undermine investor confidence.
Revenue Figures: The company reported revenue of $7.0 million, and despite the revised figure, it reflects the company's struggles in a competitive market, potentially leading to difficulties in future financing.
Financial Correction: The release emphasizes the company's efforts to ensure data accuracy, although the negative earnings may attract regulatory scrutiny, impacting its operational credibility.
Market Reaction Expectations: Given the reported losses, the market is likely to respond negatively to Sharps Technology's stock, potentially leading to further declines in share price.